Yunpeng Wang Bofang Wang Lin Xiang Junge Deng Bo Xu Puyi He Weigao Pu Haiyun Wang Yong Fan Hao Chen
10.3389/fimmu.2022.1016647
Front Immunol
2022 Oct 13;13:1016647.
anlotinib kras pd-1 inhibitor case report chemotherapy metastatic pancreatic ductal adenocarcinoma
CC BY
https://pubmed.ncbi.nlm.nih.gov/36311715/
Carcinoma, Pancreatic Ductal / drug therapy Carcinoma, Pancreatic Ductal / genetics Liver Neoplasms / drug therapy Liver Neoplasms / genetics Pancreatic Neoplasms / drug therapy Pancreatic Neoplasms / genetics Pancreatic Neoplasms / pathology
Carcinoma, Pancreatic Ductal / drug therapy Carcinoma, Pancreatic Ductal / genetics Liver Neoplasms / drug therapy Liver Neoplasms / genetics Pancreatic Neoplasms / drug therapy Pancreatic Neoplasms / genetics Pancreatic Neoplasms / pathology Review Case Reports Research Support, Non-U.S. Gov't Antineoplastic Combined Chemotherapy Protocols / therapeutic use Humans Immune Checkpoint Inhibitors / therapeutic use Proto-Oncogene Proteins p21(ras) / genetics folfirinox Immune Checkpoint Inhibitors anlotinib Proto-Oncogene Proteins p21(ras) KRAS protein, human Pancreatic Carcinoma
PMC9606775
36311715
Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review
2022